AvalehtGNLX • NASDAQ
add
Genelux Corp
2,71 $
Pärast sulgemist:(0,00%)0,00
2,71 $
Suletud: 6. märts, 16:00:09 GMT −5 · USD · NASDAQ · Välistus
Viimane sulgemishind
2,69 $
Tänane vahemik
2,58 $ - 2,74 $
Aasta vahemik
1,99 $ - 8,54 $
Turuväärtus
121,17 mln USD
Keskmine maht
196,11 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Käive | — | — |
Põhitegevusega seonduv kulu | 8,19 mln | 18,05% |
Puhastulu | −7,95 mln | −22,93% |
Puhaskasumimarginaal | — | — |
Puhaskasum aktsia kohta | −0,21 | −10,53% |
EBITDA | −8,13 mln | −18,11% |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 20,92 mln | −38,59% |
Kogu vara | 24,99 mln | −37,95% |
Kõik kohustused | 6,40 mln | −10,91% |
Kogu omakapital | 18,59 mln | — |
Emiteeritud aktsiate arv | 37,62 mln | — |
Hinna ja väärtuse suhe P/B | 5,49 | — |
Varade tasuvus | −71,58% | — |
Kapitali tasuvus | −89,42% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | −7,95 mln | −22,93% |
Põhitegevuse rahakäive | −6,58 mln | −14,39% |
Investeeringute raha | 4,72 mln | 18,26% |
Finantseerimise raha | 0,00 | — |
Raha ja raha ekvivalentide muutus | −1,85 mln | −5,58% |
Tasuta rahavoog | −4,10 mln | −27,13% |
Teave
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Asutatud
2001
Veebisait
Töötajate arv
24
